Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | TLR2 | O60603 | 3/20 | 0.36 |
| ▸ | CASP3 | P42574 | 2/20 | 0.36 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29580052 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL30063534 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL29980432 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL31013228 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL9989977 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL23200433 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL30895588 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL31284330 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL30895429 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 | |
| SCHEMBL29887767 | 1.00 | KMT2A (0.50) | KMT2AEPHX2LMNASMN1; SMN2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-24 | — | — | US | disclosed |
| US-20240060068-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-02-22 | — | — | US | disclosed |
| CN-117120456-A | Poly-morpholino oligonucleotide gap body | 卫材R&D管理有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-4259798-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | Eisai R&D Management Co., Ltd. (JP) | 2023-10-18 | — | — | EP | disclosed |
| EP-3580232-B1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20220331402-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-10-20 | — | — | US | disclosed |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-23 | — | — | US | disclosed |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022125987-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022125984-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-16 | — | — | WO | disclosed |
| US-11224634-B2 | — | — | 2022-01-18 | — | — | US | disclosed |
| US-11185570-B2 | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-30 | — | — | US | disclosed |
| US-20210196791-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2021-07-01 | — | — | US | disclosed |
| CN-110637027-A | Modified relaxin polypeptides comprising pharmacokinetic enhancers and uses thereof | 百时美施贵宝公司 | 2019-12-31 | — | — | CN | disclosed |
| US-20190256570-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2019-08-22 | — | — | US | disclosed |
| US-10266578-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2018148419-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20180222960-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12097241-B2 | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | KMT2A 3362/4885EPHX2 3868/4885LMNA 2106/4885 |
| US-20210196791-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885EPHX2 3125/4885LMNA 2133/4885 |
| US-20190256570-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885EPHX2 3125/4885LMNA 2133/4885 |
| US-20220331402-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885EPHX2 3125/4885LMNA 2133/4885 |
| US-20180222960-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885EPHX2 3125/4885LMNA 2133/4885 |
| US-11364281-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof | RXFP2, RXFP1, RXFP4 | KMT2A 2556/4885EPHX2 2970/4885LMNA 1801/4885 |
| US-20240060068-A1 | POLY-MORPHOLINO OLIGONUCLEOTIDE GAPMERS | RNMT, GAP43, MCTS1 | KMT2A 3974/4885EPHX2 4147/4885LMNA 1584/4885 |
| US-20220195437-A1 | TAU-TARGETING OLIGONUCLEOTIDE GAPMERS | MAPT, GAP43, RNMT | KMT2A 3635/4885EPHX2 4697/4885LMNA 1392/4885 |
| US-20220211812-A1 | MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885EPHX2 3125/4885LMNA 2133/4885 |
| US-11224634-B2 | — | RXFP2, RXFP1, RXFP4 | KMT2A 2489/4885EPHX2 3862/4885LMNA 2128/4885 |
| US-12097242-B2 | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | KMT2A 1915/4885EPHX2 3339/4885LMNA 2154/4885 |
| US-10266578-B2 | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | RXFP2, RXFP1, RXFP4 | KMT2A 2670/4885EPHX2 3125/4885LMNA 2133/4885 |
| US-11185570-B2 | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides | RXFP2, RXFP1, RXFP4 | KMT2A 1891/4885EPHX2 3110/4885LMNA 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.